A potentially catastrophic influenza pandemic is inevitable. Further, technology now allows the laboratory creation of highly pathogenic influenza viruses. Preparedness is vital, and it requires optimal use of the available vaccines and antivirals. Although vaccines offer the best control of influenza, at least 6 months is needed for production of a strain-specific vaccine. Therefore, antiviral drugs may be the best immediately available strategy. We hypothesize that combination therapy with two classes of anti-influenza drugs that target different viral proteins and exert different mechanisms will offer clinical and strategic advantages. This hypothesis will be tested by three specific aims. 1) To establish a reliable assay method, we will first evaluate the suitability of newly developed MDCK-SAIT1 cells, which have increased expression of humanlike sialic acid (alpha2-6 Gal-linked) receptors, for detecting drug sensitivity of emerging and resistant variants of different subtypes, including highly pathogenic viruses. 2) We will test combinations of NA inhibitors with the M2 blocker rimantadine against influenza A virus infection in MDCK-SAIT1 cells, and we will characterize their mode of interaction (additive, synergistic, or antagonistic) against human and emerging highly pathogenic H5N1 and H9N2 influenza viruses in a mouse model. 3) We will determine the effect of combination antiviral therapy on the emergence of drug-resistant variants and on clinically important properties of resistant strains, such as virulence and transmissibility. We propose to analyze a wide spectrum of influenza viruses isolated from various hosts and differing in pathogenicity. We will include recent isolates from Hong Kong, because of strong experimental evidence that the precursors of human pandemic influenza viruses originate in southern China. These findings will show 1) whether combination antiviral treatment is clinically advantageous as a response to natural or manmade highly pathogenic influenza viruses and 2) whether this strategy offers practical, economic, and public health advantages for the stockpiling and large-scale use of antivirals.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI057570-02
Application #
6841608
Study Section
Special Emphasis Panel (ZRG1-EVR (90))
Program Officer
Lacourciere, Karen A
Project Start
2004-02-01
Project End
2007-01-31
Budget Start
2005-02-01
Budget End
2007-01-31
Support Year
2
Fiscal Year
2005
Total Cost
$300,000
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Blanco, Jorge C G; Boukhvalova, Marina S; Pletneva, Lioubov M et al. (2014) A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology. Vaccine 32:1495-500
Yen, Hui-Ling; Ilyushina, Natalia A; Salomon, Rachelle et al. (2007) Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J Virol 81:12418-26
Kaverin, Nikolai V; Rudneva, Irina A; Govorkova, Elena A et al. (2007) Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J Virol 81:12911-7
Ilyushina, Natalia A; Hoffmann, Erich; Salomon, Rachelle et al. (2007) Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 12:363-70
Govorkova, Elena A; Ilyushina, Natalia A; Boltz, David A et al. (2007) Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 51:1414-24
Ilyushina, Natalia A; Govorkova, Elena A; Russell, Charles J et al. (2007) Contribution of H7 haemagglutinin to amantadine resistance and infectivity of influenza virus. J Gen Virol 88:1266-74
Ilyushina, Natalia A; Bovin, Nicolai V; Webster, Robert G et al. (2006) Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 70:121-31
Yen, Hui-Ling; Hoffmann, Erich; Taylor, Garry et al. (2006) Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol 80:8787-95
Govorkova, Elena A; Webby, Richard J; Humberd, Jennifer et al. (2006) Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 194:159-67
Yen, Hui-Ling; Herlocher, Louise M; Hoffmann, Erich et al. (2005) Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 49:4075-84

Showing the most recent 10 out of 11 publications